Morgan Stanley started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a research note released on Tuesday, Marketbeat Ratings reports. The firm issued an overweight rating and a $25.00 price target on the stock.
Separately, Stifel Nicolaus assumed coverage on shares of Contineum Therapeutics in a research note on Tuesday. They issued a buy rating and a $29.00 target price on the stock.
Check Out Our Latest Stock Analysis on Contineum Therapeutics
Contineum Therapeutics Price Performance
About Contineum Therapeutics
Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
See Also
- Five stocks we like better than Contineum Therapeutics
- How to Invest in the Best Canadian Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- What is Insider Trading? What You Can Learn from Insider Trading
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
